Cited by 998Schizophrenia research and treatmentNeurotransmitter Receptor Influence on BehaviorTreatment of Major Depression

The DOI matches its Crossref record; 390 of the 393 references it cites were found in a registry or an index.

Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs

Miyamoto, S, Duncan, G E, Marx, C E, Lieberman, J A·2005·Molecular Psychiatry

DOI 10.1038/sj.mp.4001556

Open this paper in CoChat — free account

Abstract

The treatment of schizophrenia has evolved over the past half century primarily in the context of antipsychotic drug development. Although there has been significant progress resulting in the availability and use of numerous medications, these reflect three basic classes of medications (conventional (typical), atypical and dopamine partial agonist antipsychotics) all of which, despite working by varying mechanisms of actions, act principally on dopamine systems. Many of the second-generation (atypical and dopamine partial agonist) antipsychotics are believed to offer advantages over first-generation agents in the treatment for schizophrenia. However, the pharmacological properties that confer the different therapeutic effects of the new generation of antipsychotic drugs have remained elusive, and certain side effects can still impact patient health and quality of life. Moreover, the efficacy of antipsychotic drugs is limited prompting the clinical use of adjunctive pharmacy to augment the effects of treatment. In addition, the search for novel and nondopaminergic antipsychotic drugs has not been successful to date, though numerous development strategies continue to be pursued, guided by various pathophysiologic hypotheses. This article provides a brief review and critique of the current therapeutic armamentarium for treating schizophrenia and drug development strategies and theories of mechanisms of action of antipsychotics, and focuses on novel targets for therapeutic agents for future drug development.

Integrity signals

Registry

Crossref · 10.1038/sj.mp.4001556

Cites

390 of 390 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Glutamate uptake
Danbolt, N. C. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00067-8 · Cited by 4,227
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
Implications of Normal Brain Development for the Pathogenesis of Schizophrenia
Weinberger, D. R. (1987) · Archives of General Psychiatry · doi:10.1001/archpsyc.1987.01800190080012 · Cited by 3,724
Subanesthetic Effects of the Noncompetitive NMDA Antagonist, Ketamine, in Humans: Psychotomimetic, Perceptual, Cognitive, and Neuroendocrine Responses
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
Effect of COMT Val 108/158 Met genotype on frontal lobe function and risk for schizophrenia
Egan, M. F., Goldberg, T. E., Kolachana, B. S., Callicott, J. H., Mazzanti, C. M., Straub, R. E., Goldman, D. A., & Weinberger, D. R. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.111134598 · Cited by 2,416
Antipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382
Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs
Creese, I., Burt, D. R., & Snyder, S. H. (1976) · Science · doi:10.1126/science.3854 · Cited by 2,220
Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine
Tol, H. H. M. V., Bunzow, J. R., Guan, H., Sunahara, R. K., Seeman, P. M., Niznik, H. B., & Civelli, O. (1991) · Nature · doi:10.1038/350610a0 · Cited by 2,015
Activation of Glutamatergic Neurotransmission by Ketamine: A Novel Step in the Pathway from NMDA Receptor Blockade to Dopaminergic and Cognitive Disruptions Associated with the Prefrontal Cortex
Moghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793

Show all 393 references

Research works printed but not linked: 15

Breier A, Wright P, Birkett M, Meehan K, David, Brook S . A double-blind dose response study comparing intramuscular olanzapine, haloperidol and placebo in acutely agitated schizophrenic patients, ACNP 39th Annual Meeting Abstract. American College of Neuropsychopharmacology: Puerto Rico, 2000.
Waddington J, Casey D . Comparative pharmacology of classical and novel (second-generation) antipsychotics. In: Buckley PF, Waddington JL (eds). Schizophrenia and Mood Disorders: The New Drug Therapies in Clinical Practice. Butterworth-Heinemann: Woburn, MA, 2000, pp 3–13.
Carlsson A . Focusing on dopaminergic stabilizers and 5-HT2A receptor antagonists. Curr Opin CPNS Invest Drugs 2000; 2: 22–24.
Patel JK, Pinals DA, Breier A . Schizophrenia and other psychoses. In: Tasman A, Kay J, Lieberman JA (eds). PSYCHIATRY, 2nd edn. John Wiley & Sons, Ltd: Chichester, 2003, pp 1131–1206.
Ferris P . Ziprasidone. Curr Opin CPNS Invest Drugs 2000; 2: 58–70.
Nichols DE, Mailman RB . Substituted hexa-hydro[a]phenanthridines. US Patent 1995; 5: 134.
Nichols DE, Mailman RB . Fused isoquinolines as dopamine receptor ligands. US Patent 1999; 5: 110.
Danysz W . Sonepiprazole. Curr Opin CPNS Invest Drugs 2000; 2: 97–104.
Mansbach RS, Brooks EW, Sanner MA, Zorn SH . Selective dopamine D4 receptor antagonists reverse apomorphine-induced blockade of prepulse inhibition. Psychopharmacology 1998; 135: 194–200. · DOI
Abi-Saab WM, D'Souza DC, Madonick SH, Krystal JH . Targeting the glutamate system. In: Breier A, Tran PV, Herrera JM, Tollefson GD, Bymaster FP (eds). Current Issues in the Psychopharmacology of Schizophrenia. Lippincott Williams & Wilkins Healthcare, Philadelphia, 2001, pp 304–332.
Goff D, Berman I, Posever T, Leahy L, Lynch G . A preliminary dose-escalation trial of CX 516 (ampakine) added to clozapine in schizophrenia. Schizophr Res 1999; 36: 280.
Bymaster FP . Possible role of muscarinic receptor agonists as therapeutic agents for psychosis. In: Breier A, Tran PV, Herrera JM, Tollefson GD, Bymaster FP (eds). Current Issues in the Psychopharmacology of Schizophrenia. Lippincott Williams & Wilkins Healthcare, Philadelphia, 2001, pp 333–348.
Perry KW, Bymaster FP, Shannon HE, Rasmussen K, DeLapp NW, Zhang W et al. The muscarinic agonist xanomeline has antipsychotic-like activity in animals and in man. Schizophr Res 1999; 36: 117–118.
Basile VS, Masellis M, Ozdemir V, Meltzer HY, Macciardi FM, Kennedy JL . Application of pharmacogenetics to schizophrenia: Emerging insights from studies of clozapine response and tardive dyskinesia. In: Breier A, Tran PV, Herrera JM, Tollefson GD, Bymaster FP (eds). Current Issues in the Psychopharmacology of Schizophrenia. Lippincott Williams & Wilkins Healthcare, Philadelphia, 2001, pp 85–110.
Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, Canive JM et al. The National Institute of Mental Health Clinical Antipsychotic Trials in Intervention Effectiveness (CATIE) Project: Schizophrenia trial design and protocol development. Schizophrenia Bull 2003; 29: 15–31. · DOI

Sorted by citations

Items 501–600 of 998

Antidepressant efficacy of cariprazine in bipolar disorder and the role of its pharmacodynamic properties: A hypothesis based on data
Fountoulakis, K. Ν., Ioannou, M., Tohen, M. F., Haarman, B. C. M., & Zarate, C. A. (2023) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2023.03.009 · Cited by 16
Association of dopamine receptor D1 (DRD1) polymorphisms with risperidone treatment response in Chinese schizophrenia patients
Huo, R., Wei, Z., Xiong, Y., Jiang, J., Liu, Y., Yan, Y., Shi, J., Li, W., Cui, D., Xing, Q., et al. (2014) · Neuroscience Letters · doi:10.1016/j.neulet.2014.08.041 · Cited by 17
The ocular surface side effects of an anti-psychotic drug, clozapine
Ceylan, E., Özer, M. D., Yılmaz, Y. C., Kartal, B., Ekinci, D. Y., Çinici, E., & Ceylan, N. A. (2015) · Cutaneous and Ocular Toxicology · doi:10.3109/15569527.2015.1018387 · Cited by 16
Drug treatment developments in schizophrenia and bipolar mania: latest evidence and clinical usefulness
Johnsen, E., & Kroken, R. A. (2012) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622312462275 · Cited by 20
In vivo phenotypic drug discovery: applying a behavioral assay to the discovery and optimization of novel antipsychotic agents
Shao, L., Campbell, U. C., Fang, Q. K., Powell, N. A., Campbell, J. E., JONES, P. G., Hanania, T., Alexandrov, V., Morganstern, I., Sabath, E. V., et al. (2016) · MedChemComm · doi:10.1039/c6md00128a · Cited by 16
Translational Significance of Selective Estrogen Receptor Modulators in Psychiatric Disorders
Khan, M. M. (2018) · International Journal of Endocrinology · doi:10.1155/2018/9516592 · Cited by 16
Assessments by Patients With Schizophrenia and Psychiatrists of Relative Risk of Research Procedures
Roberts, L. W., Warner, T. D., Hammond, K. G., & Dunn, L. B. (2006) · Psychiatric Services · doi:10.1176/appi.ps.57.11.1629 · Cited by 16
The ameliorating effects of 5,7-dihydroxy-6-methoxy-2(4-phenoxyphenyl)-4H-chromene-4-one, an oroxylin A derivative, against memory impairment and sensorimotor gating deficit in mice
Liu, X., Hong, S. I., Park, S. J., de la Peña, J. B., Che, H., Yoon, S. Y., Kim, D. H., Kim, J., Cai, M., Risbrough, V. B., et al. (2013) · Archives of Pharmacal Research · doi:10.1007/s12272-013-0106-6 · Cited by 16
Atypical antipsychotics antagonize GABAA receptors in the ventral tegmental area GABA neurons to relieve psychotic behaviors
Lu, C., Zhu, X., Feng, Y., Ao, W., Li, J., Gao, Z., Luo, H., Chen, M., Cai, F., Zhan, S., et al. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-01982-8 · Cited by 15
Dopamine D2 Receptor Modulates Exercise Related Effect on Cortical Excitation/Inhibition and Motor Skill Acquisition
Curtin, D., Taylor, E. M., Bellgrove, M. A., Chong, T. T. ‐., & Coxon, J. P. (2024) · Journal of Neuroscience · doi:10.1523/jneurosci.2028-23.2024 · Cited by 15
Discovery of a Novel Series of Pyrazolo[1,5-a]pyrimidine-Based Phosphodiesterase 2A Inhibitors Structurally Different from N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915), for the Treatment of Cognitive Disorders
Mikami, S., Kawasaki, M., Ikeda, S., Negoro, N., Nakamura, S., Nomura, I., Ashizawa, T., Kokubo, H., Hoffman, I., Zou, H., et al. (2017) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c17-00564 · Cited by 15
Region-specific and dose-specific effects of chronic haloperidol exposure on [3H]-flumazenil and [3H]-Ro15-4513 GABAA receptor binding sites in the rat brain
Peris-Yague, A., Kiemes, A., Cash, D., Côtel, M.-C., Singh, N., Vernon, A. C., & Modinos, G. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.10.004 · Cited by 12
Naringin treatment improved main clozapine‐induced adverse effects in rats; emphasis on weight gain, metabolic abnormalities, and agranulocytosis
George, M. Y., Menze, E. T., Esmat, A., Tadros, M. G., & El‐Demerdash, E. (2021) · Drug Development Research · doi:10.1002/ddr.21800 · Cited by 15
Ampullosporin A, a peptaibol from Sepedonium ampullosporum HKI-0053 with neuroleptic-like activity
Berek, I., Becker, A., Schröder, H., Härtl, A., Höllt, V., & Grecksch, G. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.05.012 · Cited by 15
Haloperidol-induced striatalNur77expression in a non-human primate model of tardive dyskinesia
Mahmoudi, S., Blanchet, P. J., & Lévesque, D. (2013) · European Journal of Neuroscience · doi:10.1111/ejn.12198 · Cited by 15
Association of ADRA2A and MTHFR gene polymorphisms with weight loss following antipsychotic switching to aripiprazole or ziprasidone
Roffeei, S. N., Reynolds, G. P., Zainal, N. Z., Said, M. A., Hatim, A., Adlan, A. S. A., & Mohamed, Z. (2013) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2366 · Cited by 15
Anticholinergic Use and Misuse in Psychiatry: A Comprehensive and Critical Review
Naja, W., & Halaby, A. (2017) · Journal of Alcoholism and Drug Dependence · doi:10.4172/2329-6488.1000263 · Cited by 16
Effects of Clozapine on Ethanol Withdrawal Syndrome in Rats
Kayır, H., & Uzbay, T. I. (2008) · Alcohol and Alcoholism · doi:10.1093/alcalc/agn052 · Cited by 16
Partial Dopamine D2/Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents~!2009-12-17~!2010-04-07~!2010-07-20~!
Etiévant, A. (2010) · The Open Neuropsychopharmacology Journal · doi:10.2174/1876523801003010001 · Cited by 18
Aripiprazole versus haloperidol treatment in early-stage schizophrenia
Girgis, R. R., Merrill, D. B., Vorel, S. R., Kim, E., Portland, K. B., You, M. S., Pikalov, A., Whitehead, R. E., & Lieberman, J. A. (2010) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2010.09.003 · Cited by 15
Self-citation
Action of novel antipsychotics at human dopamine D3 receptors coupled to G protein and ERK1/2 activation
Slot, L. A. B., Palmier, C., Tardif, S., & Cussac, D. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.05.006 · Cited by 15
CREB: A Promising Therapeutic Target for Treating Psychiatric Disorders
Guan, W., Meixin, N., Gu, H., & Yang, Y. (2024) · Current Neuropharmacology · doi:10.2174/1570159x22666240206111838 · Cited by 15
Increased subcortical region volume induced by electroconvulsive therapy in patients with schizophrenia
Shan, X., Zhang, H., Dong, Z., Chen, J., Liu, F., Zhao, J., Zhang, H., & Guo, W. (2021) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-021-01303-6 · Cited by 15
Animal psychotherapist: The potential impacts of animal-based tourism on mental health
Lin, G., & Li, M. (2024) · Tourism Management · doi:10.1016/j.tourman.2024.104959 · Cited by 14
Local and long-range input balance: A framework for investigating frontal cognitive circuit maturation in health and disease
Allen, S. J., & Morishita, H. (2024) · Science Advances · doi:10.1126/sciadv.adh3920 · Cited by 13
Effectiveness of positive allosteric modulators of metabotropic glutamate receptor 2/3 (mGluR2/3) in animal models of schizophrenia
Olivares-Berjaga, D., Martínez-Pinteño, A., Rodríguez, N., Mas, S., Morén, C., Parellada, E., & Gassó, P. (2025) · Translational Psychiatry · doi:10.1038/s41398-024-03194-2 · Cited by 12
Aripiprazole as the Causative Agent of Neuroleptic Malignant Syndrome
Molina, D., Tingle, L., & Liu, X. (2007) · The Primary Care Companion to The Journal of Clinical Psychiatry · doi:10.4088/pcc.v09n0211b · Cited by 14
Antipsychotic agents screened as human carbonic anhydrase I and II inhibitors
Erzengin, M., Bilen, Ç., Ergün, A., & Gençer, N. (2013) · Archives of Physiology and Biochemistry · doi:10.3109/13813455.2013.863359 · Cited by 14
A 12-month, open-label, comparative study of quetiapine and risperidone in the acute and long-term treatment of schizophrenia
Pérez, V., Cañas, F., & Tafalla, M. (2008) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3282f47c44 · Cited by 14
A Pilot Randomized, Placebo-Controlled Trial of Glycine for Treatment of Schizophrenia and Alcohol Dependence
Jane, J. S., Ralevski, E., Yoon, G., & Petrakis, I. L. (2019) · Journal of Dual Diagnosis · doi:10.1080/15504263.2018.1549764 · Cited by 14
Switching Antipsychotics to Blonanserin in Patients with Schizophrenia: An Open-label, Prospective, Multicenter Study
Woo, Y. S., Yoon, B.-H., Jeon, B.-H., Seo, J. S., Nam, B., Lee, S.-Y., Jae, Y. M., Jang, S., Eun, H. J., Won, S., et al. (2019) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2019.17.3.423 · Cited by 14
Human accelerated genome regions with value in medical genetics and drug discovery
Chu, X., Quan, Y., & Zhang, H. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.03.001 · Cited by 16
Main interactions of dopamine and risperidone with the dopamine D2 receptor
Martı́nez, A., García‐Gutiérrez, P., Zubillaga, R. A., Garza, J., & Vargas, R. (2021) · Physical Chemistry Chemical Physics · doi:10.1039/d1cp01637g · Cited by 14
Schizophrenia: What’s Arc Got to Do with It?
Managò, F., & Papaleo, F. (2017) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2017.00181 · Cited by 14
Disconnectivity between the raphe nucleus and subcortical dopamine-related regions contributes altered salience network in schizophrenia
Han, S., Cui, Q., Guo, X., Fan, Y., Guo, J., Zong, X., Hu, M., Lu, F., Chen, X., & Chen, H. (2019) · Schizophrenia Research · doi:10.1016/j.schres.2019.11.006 · Cited by 14
Chronic oral treatment with risperidone impairs recognition memory and alters brain-derived neurotrophic factor and related signaling molecules in rats
Poddar, I., Callahan, P. M., Hernandez, C. M., Pillai, A., Yang, X., Bartlett, M. G., & Terry, A. V. (2020) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2020.172853 · Cited by 14
Effects of the antipsychotic drug haloperidol on the somastostatinergic system in SH‐SY5Y neuroblastoma cells
Sánchez, J., Hernández‐Pinto, A. M., Cano-Tebar, S., Dávalos, A., Peña, G. D. L., Puebla‐Jiménez, L., Arilla, E., Lasunción, M. A., & Busto, R. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06159.x · Cited by 14
3α5β-Pregnanolone glutamate, a use-dependent NMDA antagonist, reversed spatial learning deficit in an animal model of schizophrenia.
Valeš, K., Rambousek, L., Holubová, K., Svoboda, J., Bubeníková-Valešová, V., Chodounská, H., Vyklický, L., & Stuchlík, A. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.07.020 · Cited by 15
Brain stem as a target site for the metabolic side effects of olanzapine
Anwar, I. J., Miyata, K., & Zsombok, A. (2016) · Journal of Neurophysiology · doi:10.1152/jn.00387.2015 · Cited by 13
Pharmacokinetics and central nervous system effects of the novel dopamine D 2 receptor antagonist JNJ-37822681
Beek, E. T. T., Moerland, M., de Boer, P., Nueten, L. V., de Kam, M. L., Burggraaf, J., Cohen, A. F., & van Gerven, J. M. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111415733 · Cited by 13
Pharmacogenetics and antipsychotics in the light of personalized pharmacotherapy.
Mihaljević-Peleš, A., Šagud, M., Božina, N., Živković, M., & Jovanović, N. (2010) · PubMed · Cited by 13
A low dosage of the dopamine D2-receptor antagonist sulpiride affects effort allocation for reward regardless of trait extraversion
Ohmann, H. A., Kuper, N., & Wacker, J. (2020) · Personality Neuroscience · doi:10.1017/pen.2020.7 · Cited by 14
Schizophrenia and oxidative stress from the perspective of bibliometric analysis
Chen, M.-Y., Zhang, Q., Liu, Y., Zheng, W.-Y., Si, T. L., Su, Z., Cheung, T. C. C., Jackson, T., Li, X., & Xiang, Y. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1145409 · Cited by 13
QSAR-CoMSIA applied to antipsychotic drugs with their dopamine D2 and serotonine 5HT2A membrane receptors
Avram, S., Duda-Seiman, D., Borcan, F., & Wolschann, P. (2011) · Journal of the Serbian Chemical Society · doi:10.2298/jsc100806022a · Cited by 13
3D-QSAR study indicates an enhancing effect of membrane ions on psychiatric drugs targeting serotonin receptor 5-HT1A
Avram, S., Milac, A. L., & Mihailescu, D. F. (2012) · Molecular BioSystems · doi:10.1039/c2mb00005a · Cited by 13
Drug safety and efficacy evaluation of sertindole for schizophrenia
Karamatskos, E., Lambert, M., Mulert, C., & Naber, D. (2012) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2012.726984 · Cited by 13
Quantitative structure – activity relationship studies on membrane receptors inhibition by antipsychotic drugs. Application to schizophrenia treatment
Avram, S., Berner, H., Milac, A. L., & Wolschann, P. (2008) · Monatshefte für Chemie - Chemical Monthly · doi:10.1007/s00706-007-0782-3 · Cited by 13
Effects of aripiprazole and clozapine on the treatment of glycolytic carbon in PC12 cells
Ota, A., Nakashima, A., Kaneko, Y. S., Mori, K., Nagasaki, H., Takayanagi, T., Itoh, M., Kondo, K., Nagatsu, T., & Ota, M. (2012) · Journal of Neural Transmission · doi:10.1007/s00702-012-0782-2 · Cited by 13
Antipsychotic Drugs Inhibit Platelet Aggregation via P2Y1and P2Y12Receptors
Wu, C., Tsai, F., Chen, M., Wu, S., Lee, M., Tsai, T., Wang, L., & Wang, C. (2016) · BioMed Research International · doi:10.1155/2016/2532371 · Cited by 13
Electrochemical Analysis of Antipsychotics
Karadurmuş, L., Kır, D., Kurbanoğlu, S., & Özkan, S. A. (2018) · Current Pharmaceutical Analysis · doi:10.2174/1573412914666180710114458 · Cited by 13
The Impact of Paliperidone Palmitate on Hospitalization in Patients with Schizophrenia: A Retrospective Mirror-image Study
Oh, S.-Y., Jon, D., Hong, H. J., Hong, N., Yi, J.-S., Roh, D. D., & Jung, M. H. (2019) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2019.17.4.531 · Cited by 13
Untangling Depression in Schizophrenia: The Role of Disorganized and Obsessive-Compulsive Symptoms and the Duration of Untreated Psychosis
Panov, G., Dyulgerova, S., Panova, P., & Stefanova, S. (2024) · Biomedicines · doi:10.3390/biomedicines12112646 · Cited by 12
The effects of clozapine on quinpirole-induced non-regulatory drinking and prepulse inhibition disruption in rats
Carolis, L. D., Stasi, M. A., Serlupi‐Crescenzi, O., Borsini, F., & Nencini, P. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1937-1 · Cited by 12
Socioeconomic factors influencing antipsychotic prescription for schizophrenia inpatients in China
Xue, Q., Xiong, X., Feng, Y., Yao, L., Chen, S., & Li, X. (2013) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000024 · Cited by 12
The G Protein-Coupled Glutamate Receptors as Novel Molecular Targets in Schizophrenia Treatment—A Narrative Review
Kryszkowski, W., & Boczek, T. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10071475 · Cited by 12
Increased excitatory amino acid transport into murine prion protein knockout astrocytes cultured in vitro
Pathmajeyan, M. S., Patel, S. A., Carroll, J. A., Seib, T., Striebel, J. F., Bridges, R. J., & Chesebro, B. W. (2011) · Glia · doi:10.1002/glia.21215 · Cited by 12
Long-term impacts of adolescent risperidone treatment on behavioral responsiveness to olanzapine and clozapine in adulthood
Qiao, J., Zhang, Q., & Li, M. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.10.005 · Cited by 12
Avoidance disruptive effect of clozapine and olanzapine is potentiated by increasing the test trials: Further test of the motivational salience hypothesis
Feng, M., Sui, N., & Li, M. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2012.09.013 · Cited by 12
Chronic administration of risperidone in a rat model of schizophrenia: A behavioural, morphological and molecular study
Castellano, O., Arji, M., Sancho, C., Carro, J., Riolobos, A. S., Molina, V., Gómez‐Nieto, R., Horta‐Júnior, J. D. A. C., Herrero-Turrión, M. J., & L�pez, D. E. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.12.036 · Cited by 12
Applicability of Gene Expression and Systems Biology to Develop Pharmacogenetic Predictors; Antipsychotic-Induced Extrapyramidal Symptoms as an Example
Mas, S., Gassó, P., & Lafuente, A. (2015) · Pharmacogenomics · doi:10.2217/pgs.15.134 · Cited by 12
Dissecting the Syndrome of Schizophrenia: Progress toward Clinically Useful Biomarkers
Dean, B. (2011) · Schizophrenia Research and Treatment · doi:10.1155/2011/614730 · Cited by 12
Intermittent treatment with haloperidol or quetiapine does not disrupt motor and cognitive recovery after experimental brain trauma
Weeks, J. J., Carlson, L. J., Radabaugh, H. L., de la Tremblaye, P. B., Bondi, C. O., & Kline, A. E. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.09.049 · Cited by 12
Drug-Associated Liver Injury Related to Antipsychotics
Zeiss, R., Häfner, S., Schönfeldt‐Lecuona, C., Connemann, B. J., & Gahr, M. (2022) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001576 · Cited by 12
Special Section on Implications of CATIE: What CATIE Did: Some Thoughts on Implications Deep and Wide
Owens, D. G. C. (2008) · Psychiatric Services · doi:10.1176/appi.ps.59.5.530 · Cited by 12
Alstonine as an Antipsychotic: Effects on Brain Amines and Metabolic Changes
Linck, V. M., Herrmann, A. P., Piato, Â., Detanico, B. C., Figueiró, M., Flório, J. C., Iwu, M. M., Okunji, C. O., Leal, M. B., & Elisabetsky, E. (2009) · Evidence-based Complementary and Alternative Medicine · doi:10.1093/ecam/nep002 · Cited by 12
Subsequent exposure to the choline uptake enhancer MKC-231 antagonizes phencyclidine-induced behavioral deficits and reduction in septal cholinergic neurons in rats
Shirayama, Y., Yamamoto, A., Nishimura, T., Katayama, S., & Kawahara, R. (2007) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2007.02.011 · Cited by 12
A Hybrid Indoloquinolizidine Peptide as Allosteric Modulator of Dopamine D1 Receptors
Soriano, A., Vendrell, M., Gonzalez, S., Mallol, J., Alberício, F., Royo, M., Lluís, C., Canela, E. I., Franco, R., Cortés, A., et al. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.158824 · Cited by 12
Presynaptic vesicular accumulation is required for antipsychotic efficacy in psychotic-like rats
Uzuneser, T. C., Weiss, E., Dahlmanns, J. K., Kalinichenko, L. S., Amato, D., Kornhuber, J., Alzheimer, C., Hellmann, J., Kaindl, J. M., Hübner, H., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120965908 · Cited by 11
Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments (SMART-CAT) in first-episode schizophrenia patients: Rationale and trial design
Li, X., Guo, X., Fan, X., Feng, T., Wang, C., Yao, Z., Xu, X., Chen, Z., Wang, H., Xie, S., et al. (2020) · Schizophrenia Research · doi:10.1016/j.schres.2020.11.010 · Cited by 13
Effects of Current Psychotropic Drugs on Inflammation and Immune System
Bhatt, S., Dhar, A. K., Samanta, M. K., & Suttee, A. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-981-19-7376-5_18 · Cited by 12
Salt bridge: key interaction between antipsychotics and receptors
Padilla-Bernal, G., Vargas, R., & Martı́nez, A. (2023) · Theoretical Chemistry Accounts · doi:10.1007/s00214-023-03016-6 · Cited by 11
What Remains to Be Discovered in Schizophrenia Therapeutics: Contributions by Advancing the Molecular Mechanisms of Drugs for Psychosis and Schizophrenia
Correll, C. U., Tusconi, M., Carta, M. G., & Dursun, S. M. (2024) · Biomolecules · doi:10.3390/biom14080906 · Cited by 14
Linking Genome-Wide Association Studies to Pharmacological Treatments for Psychiatric Disorders
Arnatkevičiūtė, A., Fornito, A., Tong, J., Pang, K. C., Fulcher, B., & Bellgrove, M. A. (2024) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2024.3846 · Cited by 13
Critical insights into the potential risks of antipsychotic drugs to fish, including through effects on behaviour
Wasser‐Bennett, G., Brown, A. R., Maynard, S. K., Owen, S. F., & Tyler, C. R. (2025) · Biological reviews/Biological reviews of the Cambridge Philosophical Society · doi:10.1111/brv.70031 · Cited by 13
Effects of the co‐administration of MK‐801 and clozapine on MiRNA expression profiles in rats
Huang, W., Gu, X., Wang, Y., Bi, Y., Yang, Y., Wan, G., Chen, N., & Li, K. (2021) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13576 · Cited by 11
Single-Cell RNA Sequencing and Its Applications in the Study of Psychiatric Disorders
Antunes, A. S. L. M., & Martins‐de‐Souza, D. (2022) · Biological Psychiatry Global Open Science · doi:10.1016/j.bpsgos.2022.03.013 · Cited by 14
Efficacy, safety, and tolerability of xanomeline for schizophrenia spectrum disorders: a systematic review
Leber, A., Ramachandra, R., Ceban, F., Kwan, A. T. H., Rhee, T. G., Wu, J., Cao, B., Jawad, M. Y., Teopiz, K. M., Ho, R., et al. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2334424 · Cited by 11
New prospects for antipsychotic treatment - the role of the kynurenine pathway
Karakuła‐Juchnowicz, H., Flis, M., Szymona, K., Kuczyńska, M., Stelmach, E., & Kowal-Popczak, A. (2014) · Psychiatria Polska · doi:10.12740/pp/25520 · Cited by 11
Dissociating scopolamine-induced disrupted and persistent latent inhibition: stage-dependent effects of glycine and physostigmine
Barak, S., & Weiner, I. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1785-z · Cited by 11
Schizophrenia dimension-specific antipsychotic drug action and failure in amphetamine-sensitized psychotic-like rats
Uzuneser, T. C., Schindehütte, M., Dere, E., von Hörsten, S., Kornhuber, J., Grömer, T. W., & Müller, C. P. (2018) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2018.09.005 · Cited by 11
Aripiprazole Lauroxil, a Novel Injectable Long-Acting Antipsychotic Treatment for Adults with Schizophrenia: A Comprehensive Review
Maini, K., Gould, H., Hicks, J. L., Iqbal, F., Patterson, J. C., Edinoff, A. N., Cornett, E. M., Kaye, A. M., Viswanath, O., Urits, I., et al. (2021) · Neurology International · doi:10.3390/neurolint13030029 · Cited by 12
Influence of Aripiprazole, Risperidone, and Amisulpride on Sensory and Sensorimotor Gating in Healthy ‘Low and High Gating’ Humans and Relation to Psychometry
Csomor, P., Preller, K. H., Geyer, M. A., Studerus, E., Huber, T., & Vollenweider, F. X. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.102 · Cited by 11
Synthesis and biological investigation of new equatorial (β) stereoisomers of 3-aminotropane arylamides with atypical antipsychotic profile
Stefanowicz, J., Słowiński, T., Wróbel, M. Z., Herold, F., Gomółka, A., Wesołowska, A., Jastrzębska‐Więsek, M., Partyka, A., Andres‐Mach, M., Czuczwar, S. J., et al. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.06.038 · Cited by 11
Improving our understanding of thein vivomodelling of psychotic disorders: A protocol for a systematic review and meta‐analysis
Bahor, Z., Nunes‐Fonseca, C., Thomson, L. D. G., Sena, E. S., & Macleod, M. R. (2016) · Evidence-based Preclinical Medicine · doi:10.1002/ebm2.22 · Cited by 9
PET Imaging of the 5-HT2A Receptor System: A Tool to Study the Receptor’s In Vivo Brain Function
Herth, M. M., & Knudsen, G. M. (2018) · Springer eBooks · doi:10.1007/978-3-319-70474-6_5 · Cited by 10
Prunella vulgaris Attenuates Prepulse Inhibition Deficit and Attention Disruption induced by MK‐801 in Mice
Park, S. J., Jeon, S. J., Peña, I. D., Lee, H. E., Kim, D. H., Kim, J., Lee, Y. W., Jung, J. M., Shin, B. Y., Lee, S., et al. (2013) · Phytotherapy Research · doi:10.1002/ptr.4929 · Cited by 10
Blockade of tachykinin NK3receptor reverses hypertension through a dopaminergic mechanism in the ventral tegmental area of spontaneously hypertensive rats
Gariépy, H. D. B., & Couture, R. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01008.x · Cited by 10
Pharmacogenetics of Antipsychotic-Induced Movement Disorders as a Resource for Better Understanding Parkinson’s Disease Modifier Genes
Greenbaum, L., & Lerer, B. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00027 · Cited by 10
Effectiveness of rivastigmine on positive, negative, and cognitive symptoms of schizophrenia: a double-blind clinical trial
Shafti, S. S., & Khoei, A. A. (2016) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125316656334 · Cited by 10
Treatments for Social Interaction Impairment in Animal Models of Schizophrenia: A Critical Review and Meta-analysis
Hazani, R., Michal Lavidor, B., & Weller, A. (2022) · Schizophrenia Bulletin · doi:10.1093/schbul/sbac093 · Cited by 8
Phosphodiesterases
Rotella, D. P. (2007) · Elsevier eBooks · doi:10.1016/b0-08-045044-x/00069-9 · Cited by 10
Weight change in Parkinson and Alzheimer patients taking atypical antipsychotic drugs
Sitburana, O., Rountree, S. D., & Ondo, W. G. (2008) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2008.04.026 · Cited by 10
Asthma Pharmacogenetic Study Using Finite Mixture Models to Handle Drug-Response Heterogeneity
York, T. P., Vargas-Irwin, C., Anderson, W. H., & van den Oord, E. J. C. G. (2009) · Pharmacogenomics · doi:10.2217/pgs.09.19 · Cited by 10
The audacity of proteomics: a chance to overcome current challenges in schizophrenia research
Baloyianni, N. V., & Tsangaris, G. T. (2009) · Expert Review of Proteomics · doi:10.1586/epr.09.85 · Cited by 10
Increased Presynaptic Dopamine Synthesis Capacity Is Associated With Aberrant Dopamine Neuron Activity in the Methylazoxymethanol Acetate Rodent Model Used to Study Schizophrenia-Related Pathologies
Perez, S. M., Reiley, H. B., & Lodge, D. J. (2022) · Schizophrenia Bulletin Open · doi:10.1093/schizbullopen/sgac067 · Cited by 9
Nicotinic Receptor Ligands and Novel Object Recognition
Callahan, P. M., & Terry, A. V. (2018) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-12-812012-5.00026-4 · Cited by 9
Recent Developments in Glycine Transporter-1 Inhibitors
Cioffi, C. L., Liu, S., & Wolf, M. A. (2010) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(10)45002-2 · Cited by 9
A pharmacogenetic study of risperidone on chemokine (C–C motif) ligand 2 (CCL2) in Chinese Han schizophrenia patients
Xiong, Y., Wei, Z., Huo, R., Wu, X., Shen, L., Li, Y., Gong, X., Wu, Z., Feng, G., Li, W., et al. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2014.01.017 · Cited by 9
The atypical antipsychotic olanzapine disturbs depotentiation by modulating mAChRs and impairs reversal learning
Song, W. S., Cha, J. H., Yoon, S. H., Cho, Y. S., Park, K.-Y., & Kim, M. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.11.012 · Cited by 10
Schizophrenia Aetiology and Drug Therapy: A Tale of Progressive Demystification and Strides in Management
Onaolapo, A. Y., & Onaolapo, O. J. (2018) · Advances in Pharmacology and Pharmacy · doi:10.13189/app.2018.060201 · Cited by 9

Authors: Miyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A.
Affiliations: St. Marianna University School of Medicine (JP)
University of North Carolina at Chapel Hill (US)
Duke Medical Center (US)
Corresponding author: Lieberman, J A
Venue: Molecular Psychiatry
Publisher: Springer Science and Business Media LLC
Published: 2004-08-03
Volume: 10
Issue: 1
Pages: 79-104
ISSN: 1359-4184 (ISSN-L)
1476-5578
DOI: 10.1038/sj.mp.4001556
OpenAlex: W2132980997
Cited by: 988
References: 393
Citations by year: 2026: 23 · 2025: 25 · 2024: 32 · 2023: 40 · 2022: 37 · 2021: 40 · 2020: 45 · 2019: 42 · 2018: 40 · 2017: 41 · 2016: 54 · 2015: 52 · 2014: 46 · 2013: 72 · 2012: 66
FWCI: 4.72
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Molecular Psychiatry (publishedVersion)
PubMed (publishedVersion)
Funders: National Institute of Mental Health (MH064065, P50MH064065)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Keywords: schizophrenia, antipsychotic drugs, dopamine D2 receptor, atypical antipsychotics, partial dopamine agonist, typical antipsychotics, mechanism of action, antipsychotic adverse effects, adjunctive pharmacotherapy, antipsychotic drug development, schizophrenia pathophysiology
MeSH terms: Behavioral Symptoms, Humans, Schizophrenia, Antipsychotic Agents, Drug Design, Dopamine Agents, Receptors, Dopamine D2, Receptors, Glutamate, Excitatory Amino Acid Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks